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A Model-Free Approach to Low-Dose
Extrapolation
by D. Krewski,*t D. Gaylor,t and M. Szyszkowicz*
Fimatesof ao a dwithexposuretolowleveisofca csutanespresentintheenvI aregenenaly
obtained by linearextrapolation fromhigherexposure levels atwhichriskscanbeestimateddirctly. In thispaper, we
examine thescekntific basisfor theassumption oflow-se iearity incarchogenic risk nt and the different
stati methodsthat have been proposed forlnearextrapolatin. Amodel-free appch toliearextpolationi
described and ilusttedusingepdmilogial data on rdiaction The satistcal properts ofthb metbod
areempirically assessedusing572 selectedsetsofbioassay data.
Introduction
The goal of cancer risk assessment is to predict the risk of
tumor occurrence inpeopleexposed tocarcinogenic agentspre-
sent in the environment. Such estimates of risk are useful in
assessing the potential health impact ofsuch exposures and in
evaluating risk management strategies for exposuremitigation.
In practice, cancer risk assessment is a complex process for a
complex disease. There are many different forms of cancer,
many with different disease etiologies. There exists uncertain-
ty regarding themechanisms ofinitiation, promotion, and pro-
gression ofneoplasticchanges; thepharmacokinetic distribution
ofreactivecarcinogenicmetabolites withinexposedindividuals;
and the pharmacodynamic effects oftheproximatecarcinogen
in target tissues.
The mostrelevantdataforpredictionofcancerrisk arederived
fromhumanpopulations subjected towell-characterized condi-
tions of exposure resulting in an elevated level of risk.
Epidemiological data have been ofgreat value in identifying a
number of agents capable of causing cancer in humans, par-
ticularlythroughobservations oncertainoccupational groups or
individuals exposed tomoderately highlevelsoftheagentofin-
terest. Toestimate thepotential risks associated with lower en-
vironmental exposures, downward extrapolation ofthese results
may be required.
In many cases, epidemiological data on a suspectcarcinogen
may be nonexistent or inadequate for purposes ofquantitative
risk assessment. This can occurdue to alackofaccurate infor-
mation on exposure levels or the presence ofconfounding risk
factors. In this event, prediction ofhuman cancer risks may be
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attempted using laboratory studies ofcarcinogenicity, on the
basis that animal carcinogens are presumptive human car-
cinogens(I)andthatsomedegreeofcorrelationincarcinogenic
potencyexistsbetweenanimalsandhumans(2). Becauseofthe
needtoelicitpotentialtoxiceffectsusingalimitednumberofex-
perimental subjects, the doses used in laboratory studies are
generallymuchhigherthanhumanexposurelevels. Consequent-
ly,theneedtoextrapolatefromhightolowdosesalsoariseswith
toxicological data.
Pastapproaches to the low-dose extrapolation problem have
reliedonanassumedmathematical functionrelatingcancerrisk
toexposure. Therearemanydifferentcandidatesforsuchadose-
responsemodel, somewithstrongerbiologicalbasesthanothers
(3). Tolerance distribution models such as the probit and logit
havegenerallyevolvedinthestudyofnoncarcinogenicendpoints
to describe dose-response relationships in the observable
responserange. Mechanistic models describecarcinogenesis as
astochasticmultistageprocess, inwhichneoplasticconversion
ofstemcellsproceedsthroughaseriesofwell-definedstagesin-
volvingbothgeneticdamageandchangesincellkinetics. Unfor-
tunately, with the limited information provided by
epidemiological and toxicological studies, it is possible to
postulatedifferentmodelsthatfitthedataequallywell,butwhich
providepointestimatesofriskatlowdosesthatdifferby several
ordersofmagnitude (4).
The purpose ofthis paper is to provide aprocedure for low-
doseriskestimationthatdoes notdependupontheselectionof
a specific dose-response model. Our goal is to obtain the best
possibleupperconfidencelimitonlow-doseriskusingonlydata
ontumoroccurrenceratesfromepidemiologicalortoxicological
studies. Theonlyassumptionmadeisthattheunderlyingdose-
responsecurveislinearorsublinearatlowdoses. Estimatesof
low-doseriskbasedonthemodel-freeprocedureproposedinthis
paperarecomparedwithcorrespondingestimatesbasedonthe
linearized multistage model using a large number ofdata sets
previously reported intheliterature.KREWSKJETAL.
Carcinogenic RiskAssessment
Multistage Model
Themultistagemodeliscurrentlythemostwidelyusedmodel
forcancerriskestimation. AsformulatedbyArmitageandDoll
(5), theprobabilityP(d)ofatumoroccurringfollowingexposure
to a fixed dosedup to timetis givenby
P(d) = 1 - exp [_ck n (a, + b4)J (1)
i-I
wherei = 1,... ,kindexesthedistinctstagesofak-stageprocess.
Here, ai+b,drepresents the rateatwhichtransitions to stage i
occur, witha, >0denotingthespontaneoustransitionrateand
bjd (bj2 0) representingtheeffectsofdosed. (Theconstantcis
proportionaltothenumberofindividualcellsatriskinthetauget
tissue.) This model predicts that the age-specific cancer in-
cidencerateswillbeproportionaltoageraisedtothepower(k-i)
and provides a good description of human cancer incidence
curves with2 .k . 6.
For applications, Crump et al. (6) proposed the modified
multistage model
P(d) = 1 - exp [-ctk E (qjd)] (2)
i-O
wheretheq* 2 0. Although theclassofpolynomials with non-
negative coefficients included in the exponent in Eq. (2) is
broaderthanthecorresponding class inEq. (1), thisformulation
iseasiertoapply intermsofparameterestimation. Forsmalld,
wehave
P(d)-P(0)= qld (3)
l-P(O)
Thus, whenthebackgroundP(O)issmall,qI representstheslope
ofthedose-responsecurveinthelow-doseregion. Althoughthe
original model [Eq. (1)] islinear atlowdoses, theextension in
Eq. (2) allows for the case q, = 0. In practice, an upper con-
fidence limit ql(O is used, which will be strictly positive (7).
This upper bound has come to be known asqt andprovides a
measure of carcinogenic potency based on the linearized
multistage (LMS) model.
PointEstimates Versus Confidence Limits
Theuseofa95% upperconfidence limitonq1 ratherthanits
maximum likelihood estimate has been the subject of some
discussion. Proponentsofbestestimatesarguethattheuseofup-
perconfidencelimitsleadstounwarrantedconservatisminrisk
estimation(8). Whendecision-makingallowsfor alaingrisks
against benefits, it has also been argued that bestestimates of
benefit should be compared to best estimates of risk. Upper
bounds on riskbased on the linearized multistage model have
alsobeencriticizedinthattheyarehighlyinsensitivetothedata
on which they arebased(9).
Forvariousreasons, theU.S. Environmental ProtectionAgen-
cy (10) hastakenthepositionthat, ingeneral, bestestimates of
riskcannotbereliably computed atthistime. Intheabsenceof
asuitablebestestimateofrisk, theAgencyadvocatestheuseof
linearizedupperbounds. Thispositionisbasedinpartonthefact
thatthebestestimate ofq, maybe0, inconflict with the strict
linearity impliedbyEq. (1). Evenwhenpositive, themaximum
likelihoodestimatorofq,canberelativelyunstable, withminor
perturbations to the data resulting in marked changes in its
estimated value(11).
Biologically Based CancerModels
TheArmitage-Doll modelhasbeensubjecttocriticismsthat
itdoesnotprovideacompletedescriptionoftheprocessofcar-
cinogenesis. Specifically, thek-stagesenvisagedinthemodelare
largelyphenomenologicalanddonotnecessarilyrepresentwell-
definedbiological changes. Inparticular, when the number of
stages required to fitthedata is large, itisdifficultto interpret
thesestagesasspecificmutational events. Themodelalso fails
toprovideforthedevelopmentoftargettissueswithageandfor
thedynamics ofcells involved inneoplastic conversion.
Moolgavkar(12)andhisco-workers(13,14)havedevelopeda
two-stage biologically based model ofcarcinogenesis that ex-
plicitlyprovidesfortissuegrowthandcellkinetics. Thismodel
assumesthattwomutations,eachoccurringduringcelldivision,
arerequired fora stemcell tobetransfonned into amalignant
cancercell. Initiatedcellsthathavesustainedthefirstmutation
may be promoted through nongenotoxic mechanisms that in-
creasethenetbirthrateofinitiatedcells. ThorslundandCharnley
(15)haveappliedaformofthismodelintheestimationofcancer
risksassociatedwithexposuretochlordaneanddioxin. However,
theestimability oftheunknownmodelparametersrequiresfur-
therstudy (16).
Range-of-RiskEstimates
Sinceprecisemechanismsofcarcinogenicactionaregeneally
unknon, itfollowsthatnomodel, nomatterhowelaborate, can
claimtobecorrect. Thisuncertaintyhaspromptdproposasfor
theuseofarange-of-riskestimatesbasedondifferentplausible
models. Calculation ofarange-of-point estimates serves little
usefulpurposeanddoesnotcontribute to arealunderstanding
of the uncertainty in the extrapolation process. Since point
estimatesdependonthefonnofthemodelselected,thenumber
of point estimates is limited only by the number of models
entertained.
Inourview,amorerealisticapproachtoexpressinguncertain-
tyistorecognizethattheriskcouldbeashighasthatpredicted
bylinearextrapolation oraslowas0. Theriskwillbe0whena
thrshldexistsbelowwhichneoplasticconversiondoesnotoc-
cur. Paynteretal. (17)havesuggestedthatathresholdmayexist
forthyroidtumorinduction, althoughtheevidenceindtisregard
is notconclusive.
IsLinearExtrapolationConservative?
Linearextrapolation often is criticized as being too conser-
vative. Schell andLeysieffer (18) showthattheone-hitmodel,
which is linear at low to moderate doses, provides an upper
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boundonriskforanydose-responsemodelsatisfyinganincreas-
ing failure rate condition with dose. (This condition holds for
commonlyencountereddose-responsemodels,theprobitmodel
beinganexception.)Bailaretal. (19) showthatasignificantfrac-
tionofbioassaysconductedfortheNationalToxicologyProgram
demonstratesupralinearityathighexperimentaldosesandargue
thatatlowdosestheone-hitmodelmaythusnotbeconservative
in some cases. Crump et al. (20), Peto (2I), and Hoel (22) all
arguethatlow-doselinearity occurswhensubstancesaugment
existingcarcinogenicprocesses. TheformationofDNAadducts,
whichmaybepredictiveofcertaintumorsinducedbygenotox-
iccarcinogens, hasoftenbeenobservedtobelinearatverylow
doses (23,24). The question is thus not so much if low-dose
linearityexists,butoverwhatrangethedoseresponseisapprox-
imately linear. Forthemultistagemodel, Crumpetal.(20)have
shown that linearextrapolation will be quite accurate, at least
when the excess riskdoes notexceedthe spontaneous risk.
TIssueDosimetry
Measurementsorpredictionsofthedoseoftheproximatecar-
cinogenreachingthetargettissuecanbeusedtoobtainmoreac-
curate estimates of low-dose risks. This can be done using
physiologically based pharmacokinetic (PBPK) models that
describethefateofchemicalsubstancesinthebody(25). These
modelsdescribemetabolicprocesseswithinanumberofrelevant
physiological compartmentsandhavebeensuccessfullyusedto
model the metabolism ofseveral chemicalcarcinogens (26).
Whenoneormorestepsintheprocessofmetabolicactivation
aresaturable, thedosedeliveredtothetargettissuemay notbe
directly proportional to the administered dose (27). In such
cases, risk estimates based on the administered dose can be
biased(28). Atsufficientlylowdoses,however,mostkineticpro-
cesseswillbefirst-order, inwhichcasetherelationshipbetween
external andinternal doses willbelinear.
Linear Extrapolation
We have argued that dose-response curves for some car-
cinogensmaybeexpectedtobelinearatlowdoses. Ifthedose-
response curve is actually sublinear in the low-dose region,
linearextrapolationprovidesanupperlimitonlow-doserisk. In
this section, we first review previously proposed methods for
linearextrapolationandthendescribeourmodel-freeapproach.
PrviousApproaches
Gross et al. (29) suggested a method for linear model ex-
trapolationbasedondiscardingdatastartingattheupperendof
thedoserangeuntilalinearmodelprvidedanadequatedescrip-
tionoftheremaining data. VanRyzin(30) suggestedtheuseof
anymodelthatfitthedatareasonably welltoestimatethedose
producinganexcessriskof1% andthenusingsimplelinearex-
trapolationtolowerdoses. GaylorandKodell(31)proposedfit-
tingamodeltotheaailabledataandthenusinglinearexutapola-
tion below the lowest dose at which observations were taken.
Sincetheesimate atthelowerdosesmightbeundulyinfluenced
bythechoiceofthemodelusedintheexperimentaldoserange,
Famieretal. (32)suggestedlinerexrapolabonbelowthelowest
dose or the dose corresponding to an estimated risk of 1%,
whicheverwas larger.
Krewskietal. (33)proposeanentirelymodel-freeprocedure
basedonlinearextrapolationbelowthelowestdoseshowingan
excess(notnecessarily statistically significant)risk. Krewskiet
al. (34)modifiedtheirproceduretoconsiderlinearextaplation
fiomalldosesforwhichtherewerenostatisticallysignificantin-
creasesintumorincidenceabovethebaselinelevel,selectingthe
smallest slope for low-dose riskestimation. In a similar vein,
Gaylor(35)consideredthesmallestslopeobtainedfromallthe
possiblecombinations ofdatafromthedoses wherethelowest
dose was in the convex portionofthe dose-response curve. In
both cases, upper confidence limits on the slopes were used.
Both Krewski etal. (33) andGaylor (35) showedthatlow dose
risk estimates based on these model-free procedures were
generallyclosetothoseobtainedfromthelinearizedmultistage
model.
Model-Fre Approach
The only assumption that we wish to entertain in assessing
low-dose cancer risks is that oflinearity ofthe dose-response
curveatlowdoses. Underthisassumption, low-doseriskassess-
mentrequiresestimationoftheslopeofthedose-responseatthe
origin givenby
> 0
Ad d=O
(4)
Withoutmakingspecificassumptionsconcerningthefunctional
formofthedose-responsecurveotherthanlow-doselinearity,
anaturalestimatorof( atadosedclosetoOwouldbetheslope
ad = [P(d) - P(O)J/d (5)
ofthe secantfrom (d, P(d)) to (0, P(0)), sinceId-+f asd - 0.
This approximation suggests a simple model-free approach to
linearextrapolation.
Consider a bioassay with t+l dose levels 0 = do < d1
<.. .<d,wheredo = 0 corresponds tothecontrol group. Of
then1 animulsatdosed1, supposethatx,developthelesionofin-
terestduring thecourse ofthe study (i=0, 1, ... ,t). Theprob-
abilityp,oftumordevelopmentatdosed,may thenbeestimated
by , = x;In,. Linearinterpolationbetween apoint
- (I <i .
t) andj- yieldsthe secantapproximation to the linear compo-
nentofthedose-responsecurve.
To ensure that this approximation is reasonable, we need to
restrictthe set[Pj, * **,P,3 to somesubset.., * * * P,.] ofpoints
(1 5 1* S t)suchthatthissubsetlieswithinaregionofthedose-
response curve in which the secant approximations will not
underestimatethelow-doseslope. Aftersmoothingthepropor-
tions so as to form a monotonically increasing set [pj3 using
isotonicregression, Gaylor(35) selectedP'tocorrespondtothe
convexregionofthedose-responsecurve. Schmoyer(36)used
sigmoidal regression to smooth the dose-response curve,
yielding a value of t* up to which the smoothed proportions
would be convex. Both of these smoothing procedures can
notablyalterobservedproportions [Pj. Isotonicandsigmoidal
regressionalsoraisetechnicalcomplicationswhenconfidence
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limits on the smoothed proportions [fr} areconsidered (37).
Krewski etal. (34)adopted asimplerapproachinwhicht* was
chosen tocorrespond tobethelargestdosebelowthefirstdose
atwhichtheobserved response rate amongtheexposed groups
was significantly greater than the response in controls. (Here,
statistical significance is evaluated at the 5% level using the
Fisher-Irwinexacttest.)Ifthelowestdoseexhibits astatistical-
ly significant increase in tumors, only this dose is used for ex-
trapolation. In this case, the results should be interpreted with
caution sincethereisless assuranceofconvexity. Toallowfor ex-
perimental error, an exactbinomial upper confidencelimitp1'O
was calculated onp, (i=1, ...t*), alongwith alowerconfidence
limitpo(L) onpo. The minimum (positive) valueofthet* secants
(Pil -po(L)I)di(i=l, . . .,t*) isthenused as anupperconfidence
limit onthelow-doseslope. Because nodose-responsemodelhas
been assumed, we refer to this as model-free extrapolation
(MFX).
Because theminimum ofup to tsuch secants is selected, the
overall confidence level associated withthisprocedurerequires
consideration. BytheBonferroni inequality, an overall95% con-
fidencelevel maybeachievedusingindividualconfidence limits
of5/(t+1)%. Since not all t secants are used whent* < t, it is
possiblethatthisBonferronibound maybeimproved upon. This
is currently under investigation.
Illustrative Examples
To illustrate the application of the model-free approach to
linearextrapolation, weconsiderthedata onradiation-induced
stomach cancer shown in Table 1, previously analyzed by
Krewski et al. (34). These data are shown in graphical form in
Figure IAafterre-expression intermsofrelativerisk. The secant
bounds based on those exposure groups not demonstrating a
significant increase in risk (p < 0.05) are shown in Figure 1B.
The secantwiththesmallestsloperepresentstheMFXbound on
low-dose risk.
To comparetheMFXapproachwiththetraditional LMS, con-
siderthebioassaydatashowninTable2 onkidneytumorsinduc-
ed in Fischer344 rats followingoral exposure tonitrilotriacetic
acid (NTA) for 24 months (38). These same data aredisplayed
graphically inFigure2A, alongwiththefittedmultistagemodel
(39). Thebest-fittingmodelinvolvesfivestagesbutdoesprovide
agood description ofthedose-response curve.
The (100 - 5/6) = 99.17% upper confidence limits on the
responseprobabilities ineachoftheexposed groups are shown
inFigure2B,along withtheassociatedsecantbounds onthelow-
dose slope. (No secant is shown for thedoseof2% NTA in the
diet, since the tumor response at this dose was significantly
Table 1. Deaths from stomach cancer in
A-bomb survivors in Hiroshima andNagasaid.
Dose, Number Number Proportion
rads responding at risk responding
0 708 31581 0.02242
3.4 473 23073 0.02050
21.8 340 14942 0.02275
70.6 91 4225 0.02154
142.4 64 3128 0.02046
243.6 32 1381 0.02317
345.3 17 639 0.02660
526.4 29 887 0.03269
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FIGURE 1. Deaths from stomach cancer in A-bomb survivors in Hiroshima and
Nagasaki.
Table2. Kidney tumors in Fischer 344 ratsexposed to
nitrilotriacetic acid for 24 months.
Dose, Number Number Proportion
indiet responding at risk responding
0 0 127 0
0.02 0 48 0
0.20 0 48 0
0.75 1 91 0.011
1.50 2 91 0.022
2.00 12 48 0.250
greater than 0, the control response.) The minimum slope of
these secants occurs at adoseof1.5% andhas avalueof0.061
per percent NTA in the diet.
To compare the MFX approach with the traditional LMS,
considerthebioassay data shown inTable2 on kidney tumors
induced in Fischer 344 rats following oral exposure to
nitrilotriacetic acid(NTA)for24 months(38). These samedata
are displayed graphically in Figure 2A, along with the fitted
multistage model (39). The best-fitting model involves five
stagesbutdoesprovide agooddescriptionofthedose-response
curve.
The (100 - 5/6) = 99.17% upperconfidence limits on the
responseprobabilities ineachoftheexposed groups areshown
in Figure 2B, along with the associated secant bounds on the
se Slope * Observed Data b. Bounds on Low Dos
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FIGURE2. Kidndey tumors in Fischer rats exposed to nitri
months.
low-dose slope. (No secant is shownforthed4
thediet, sincethe tumor response atthis dose
greater than 0, the control response.) The nf
these secants occurs at adoseof1.5% andhas a
XTIr-A :_ 4-1* A:-
sidered to avoid studies with larger mammals such as dogs or
Dose Response monkeysinwhichexposureoccurredoverarelativelysmallfrac-
tion oftheir lifespan. Second, experiments in which exposure
took place by more than one route were excluded because of
pharmacokineticcomplications arisingwithmultipleexposure
routes. Third,onlyexperimentswithatleasttwodosegroups(in
addition totheunexposedcontrol group) wereused inkeeping
withminimal standardsofbioassaydesign. Fourth,experiments
with reduced survival among exposed animals were excluded
sincethiscouldbiastumoroccurrenceratesdownward. (Using
onlylowdoseswithMFXwouldhelptoalleviatethisproblem,
as reduced survival generally occurs athigherdoses.)
Experimentsselectedaccordingtothesecriteriaoftenincluded
dataontumoroccurrenceatmorethanonesite. Grossaggrega-
1b50 2-00 tionsofsites(alltargetsitesortumorbearinganimals) wereex-
cluded on the basis that most carcinogens appear to be site
Low Dose Slope specific. Similarly, aggregationsofall tumorsatagivensitewere
omitted. Forourpurposes, onlythemostsignificantsitewascon-
sidered, thisbeingthesiteonwhichmostconcernwouldlikely
focusinpractice. Here, significancewasdefinedintermsofthe
p-valueoftheCochran-Armitagetestforincreasinglineartrend
intumorresponsewithincreasingdose(43). Incaseswheretwo
or more sites had the samep-value, the one with the smallest
TD5o(thedoseresulting in50% tumorincidence) wasselected.
Toensurethatcompoundsselected foranalysiswereconsidered
insomesensetobecarcinogens, onlythoseresultsforwhichthe
(one-sided)p-valueforthetrendtestwaslessthan 1% weread-
mitted. Additionalevidenceofcarcinogenicity wasrequiredby
1-50 2t00 further demanding an expressed opinion by the original in-
vestigators thatthe compound was considered carcinogenic.
ApplicationofthesecriteriatotheGolddatabaseyielded585
ilotriaceticacidfor24 experiments foranalysis. Theslopeofthedose-response curve
attheoriginwasestimatedusingMFXandtheLMSmodel. In
thelatteranalyses, dosesassociatedwithadownturninthedose-
ose of2 % NTA in response curveathighdoses wereomitted. In 13 cases, the sam- oseof2% NTAin ple size limitations for MFX were exceeded. This left 572 ex-
wassignificantly periments forcomparison purposes.
unimum slope of Thedistributionoftheratios(MFX/LMS)ofthetwoestimates
valueof0.061 per across the572 data sets is shown in Figure 3. Themedian ratio
percent N IA intne wiet.
An upperconfidence limit on the slope ofthe dose-response
curveattheorigincanalsobederivedundertheLMSmodel. For
comparability withMFX, thisiscalculated as 10-2/d* whered*
represents a95% lowerconfidencelimitonthedosecorrespon-
dingtoanadditionalriskof1%(39). (Thisdiffersslightlyfromq*
whenthebackground tumorresponserateisnotlow.)Thisleads
toaslopeof0.024, afactorof2.5lowerthanobtainedwithMFX.
Empirical Evaluation
The general performance of our model-free extrapolation
(MFX) procedure in comparison with thetraditional LMS may
be empirically evaluated by applying both methods to ex-
perimental data on a moreextensiveseriesoftestcompounds. In
thisregard, Goldetal. (40-42)haveassembled auseful reference
databaseofbioassaydatadrawnfrom3749experimentsreported
intheliterature. Here, anexperimentisdefinedintermsofresults
for one sex ofone species from one research report.
For our purposes, a subset ofthis database was selected for
analysis. First, only data onrats, mice, andhamsters were con-
am
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was 1.3, indicating a tendency toward slightly higher slope
estimates with MFX than with LMS. In 443 of572 cases, the
MFX estimate was withinafactoroftwoofthe LMSestimate.
Therewereeightinstances inwhichMFXexceededLMSby
a factor of more than 10-fold. A case-by-case examination of
thosecasesrevealed alevelingofforevenadecreaseinthedose-
responsecurveathigherdoses, whichtendedtoreducethevalue
ofq*. SinceMFXdoesnotgenerallyusehigh-dosedata, ahigher
(and likely more accurate) estimate of the slope of the dose-
response curve at low doses isobtained.
Summary and Conclusions
Thequantitativeassessmentofrisksassociatedwithlow-level
exposuretocarcinogenspresentintheenvironmentcontinuesto
beanimportantproblemuponwhichconsensusremainstobeat-
tained. Thisissueisparticularlycontentious whenextrapolations
notonly fromhightolowdosesbutfromlaboratory animals to
humans must be made. Nonetheless, such estimates are often
needed forpurposes ofriskmanagement.
TheLMSmodelhastraditionallybeenusedforlow-doserisk
estimation. Itisnowwidelyrecognizedthatthismodelprovides
an incomplete description of chemical and radiation car-
cinogenesis, neglectingimportantfactorssuchastissuegrowth
andcell kinetics. Dose-response relationshipsdemonstratinga
high degree ofcurvature at high doses can occur as a result of
cellular proliferation or saturation ofmetabolic processes re-
quired to formtheproximate carcinogen, butcanbeexplained
only with a large number of stages in the multistage model.
Although morebiologically basedmodelshaveemergedwithin
the last decade, these models involve additional unknown
parameters that may not be directly estimable using
epidemiological ortoxicologicaldataontumoroccurrencerates.
Irrespective ofthe actual dose-response model, there are a
numberofarguments thatsuggestthatthedose-responsecurve
maybelinearatlowdoses. Specifically, low-doselinearitymay
beexpectedtoholdwithagentsthatactbyaugmentingongoing
carcinogenic processes. DNA adducts formed with genotoxic
carcinogensalsoappeartobelinearly relatedtodoseatlowlevels
ofexposure.
Forthesereasons, amodel-freeapproachtocarcinogenicrisk
assessment thatassumesnothing more than low-dose linearity
seems appealing. The model-free extrapolation (MFX) pro-
ceduredescribedinthisarticleisbasedonaseriesofsecantap-
proximationstotheslopeofthedose-responsecurveinthelow-
doseregion, withtheminimumofsuchapproximations selected
forriskassessmentpurposes. Thisrepresentsthebestuppercon-
fidence limit on low-dose risk consistent with thedata.
Ananalysisof572experimentsdemonstratedthatMFXyields
estimates oflow-dose riskarelargely comparable toestimates
derivedundertheLMSmodel. Inadditiontomakingaminimal
numberofassumptions, MFXdoesnotmakeuseofdataathigh
doseswheresurvival maybeimpairedornormalphysiological
function disrupted.
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